CDNA CareDx, Inc
$21.63
Platform & Compounding FCF 50%
Two-stage FCF DCF
Strong · Conviction

Overvalued

Trading 91.3% above fair value

You pay $21.63
Bear $8.86
Fair $11.30
Bull $14.00
Bear $8.86 -59.1% 9% stage 1 growth, 12% discount
Fair $11.30 -47.7% 15% stage 1 growth, 12% discount
Bull $14.00 -35.3% 19% stage 1 growth, 12% discount

Key Value Driver

FCF growth rate (15% base case)

Terminal Value % of EV 38%
Implied Market Multiple 96.3x

Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $24.00 from 13 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $11.30 per share.

Warnings

Wall Street's average price target is $24.00 (from 13 analysts). Our estimate is 66% below the consensus -- consider that gap carefully.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions